Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
US11046764B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 3, 2018 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Apr 21, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.